- Home
- ZD vs BBOT Comparison
ZD vs BBOT Comparison
Compare ZD & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZD | BBOT |
|---|---|---|
| Founded | 1995 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZD | BBOT |
|---|---|---|
| Price | $27.16 | $10.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $36.50 | $23.71 |
| AVG Volume (30 Days) | ★ 693.3K | 280.4K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,364,028,000.00 | N/A |
| Revenue This Year | $6.73 | N/A |
| Revenue Next Year | $3.36 | N/A |
| P/E Ratio | $24.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.45 | $8.70 |
| 52 Week High | $43.54 | $14.87 |
Technical Indicators
Market Signals| Indicator | ZD | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 31.59 | 39.03 |
| Support Level | N/A | $9.55 |
| Resistance Level | $33.47 | $12.65 |
| Average True Range (ATR) | 2.00 | 0.72 |
| MACD | -0.45 | -0.06 |
| Stochastic Oscillator | 40.23 | 7.80 |
Price Performance
Historical ComparisonAbout ZD Ziff Davis Inc.
Ziff Davis Inc is a focused digital media and internet company whose portfolio includes brands in technology, entertainment, shopping, health, cybersecurity, and martech. It has two reportable segments: Digital Media and Cybersecurity and Martech. The company's brands include Mashable, Ookla, Offers.com, IGN, and VPN among others. The majority of revenue is generated from Digital Media.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.